Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

147 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Effects of exenatide once weekly plus dapagliflozin, exenatide once weekly, or dapagliflozin, added to metformin monotherapy, on body weight, systolic blood pressure, and triglycerides in patients with type 2 diabetes in the DURATION-8 study.
Jabbour SA, Frías JP, Guja C, Hardy E, Ahmed A, Öhman P. Jabbour SA, et al. Among authors: frias jp. Diabetes Obes Metab. 2018 Jun;20(6):1515-1519. doi: 10.1111/dom.13206. Epub 2018 Feb 4. Diabetes Obes Metab. 2018. PMID: 29316164 Free PMC article. Clinical Trial.
Effects of exenatide once weekly plus dapagliflozin, exenatide once weekly alone, or dapagliflozin alone added to metformin monotherapy in subgroups of patients with type 2 diabetes in the DURATION-8 randomized controlled trial.
Frías JP, Hardy E, Ahmed A, Öhman P, Jabbour S, Wang H, Guja C. Frías JP, et al. Diabetes Obes Metab. 2018 Jun;20(6):1520-1525. doi: 10.1111/dom.13296. Epub 2018 Apr 19. Diabetes Obes Metab. 2018. PMID: 29573139 Free PMC article. Clinical Trial.
More patients reach glycaemic control with a fixed-ratio combination of insulin glargine and lixisenatide (iGlarLixi) than with basal insulin at 12 weeks of treatment: A post hoc time-to-control analysis of LixiLan-O and LixiLan-L.
Frias J, Puig Domingo M, Meneghini L, Napoli R, Liu M, Soltes Rak E, Aroda VR. Frias J, et al. Diabetes Obes Metab. 2018 Sep;20(9):2314-2318. doi: 10.1111/dom.13368. Epub 2018 Jun 13. Diabetes Obes Metab. 2018. PMID: 29785837 Free PMC article.
Efficacy and Safety of Dapagliflozin in Patients With Inadequately Controlled Type 1 Diabetes (the DEPICT-2 Study): 24-Week Results From a Randomized Controlled Trial.
Mathieu C, Dandona P, Gillard P, Senior P, Hasslacher C, Araki E, Lind M, Bain SC, Jabbour S, Arya N, Hansen L, Thorén F, Langkilde AM; DEPICT-2 Investigators. Mathieu C, et al. Diabetes Care. 2018 Sep;41(9):1938-1946. doi: 10.2337/dc18-0623. Epub 2018 Jul 19. Diabetes Care. 2018. PMID: 30026335 Free article. Clinical Trial.
Double-blind, randomized clinical trial assessing the efficacy and safety of early initiation of sitagliptin during metformin uptitration in the treatment of patients with type 2 diabetes: The CompoSIT-M study.
Frias JP, Zimmer Z, Lam RLH, Amorin G, Ntabadde C, Iredale C, O'Neill EA, Engel SS, Kaufman KD, Makimura H, Crutchlow MF. Frias JP, et al. Diabetes Obes Metab. 2019 May;21(5):1128-1135. doi: 10.1111/dom.13626. Epub 2019 Feb 17. Diabetes Obes Metab. 2019. PMID: 30609212 Free PMC article. Clinical Trial.
147 results